ICU Medical, Inc. $ICUI Shares Sold by Granite Investment Partners LLC

Granite Investment Partners LLC cut its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 14.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 77,167 shares of the medical instruments supplier’s stock after selling 12,585 shares during the quarter. Granite Investment Partners LLC owned about 0.31% of ICU Medical worth $9,257,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ICUI. Cullen Frost Bankers Inc. acquired a new position in shares of ICU Medical during the second quarter valued at about $38,000. SJS Investment Consulting Inc. increased its stake in ICU Medical by 41,000.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 410 shares in the last quarter. Covestor Ltd raised its holdings in shares of ICU Medical by 70.7% in the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock worth $68,000 after buying an additional 236 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after buying an additional 101 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of ICU Medical during the second quarter worth $177,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a report on Sunday, February 15th. Piper Sandler lifted their target price on ICU Medical from $172.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday. Finally, KeyCorp increased their price target on shares of ICU Medical from $175.00 to $180.00 and gave the stock an “overweight” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ICU Medical currently has an average rating of “Moderate Buy” and a consensus target price of $179.33.

ICU Medical Stock Performance

Shares of ICUI stock opened at $157.03 on Monday. ICU Medical, Inc. has a 52-week low of $107.00 and a 52-week high of $164.35. The company has a quick ratio of 1.15, a current ratio of 2.39 and a debt-to-equity ratio of 0.60. The stock has a market cap of $3.88 billion, a PE ratio of 7,855.43 and a beta of 0.79. The business has a 50-day simple moving average of $149.40 and a 200-day simple moving average of $135.99.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.23. ICU Medical had a return on equity of 7.33% and a net margin of 0.03%.The company had revenue of $535.94 million during the quarter, compared to analysts’ expectations of $541.20 million. During the same period last year, the business earned $2.11 earnings per share. ICU Medical’s quarterly revenue was down 14.1% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, equities analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current year.

Key Headlines Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q4 EPS beat street estimates — ICU Medical reported $1.91 EPS vs. the consensus $1.68, a surprise on the bottom line that helped lift sentiment. Earnings and Revenues Surpass Estimates
• Positive Sentiment: Company raised FY2026 EPS guidance to a range of $7.75–$8.45, above the consensus ~7.41, signaling confidence in the outlook and likely supporting the rally. Company Press Release
• Positive Sentiment: Sell-side support: Piper Sandler reiterated a Buy rating, which can sustain investor demand following results. Piper Sandler Rating
• Neutral Sentiment: Board action to extend an executive severance plan was announced as a measure to preserve leadership stability — governance/retention detail that reduces execution risk but is not a direct earnings driver. Severance Plan Extension
• Neutral Sentiment: Company published the earnings slide deck and call transcript for investors to review management commentary and details on margins, supply chain and demand trends. Earnings Call Transcript
• Negative Sentiment: Revenue slightly missed expectations at $535.94M vs. $541.20M est. and was down ~14% year‑over‑year, highlighting ongoing demand weakness that investors will watch for reversal. Q4 Results and Guidance
• Negative Sentiment: Profitability pressure: EPS declined from $2.11 a year ago to $1.91 and the company reported a slightly negative net margin, underscoring margin and volume headwinds. Investor Presentation / Press Release

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.